Anemia trials: Lessons for clinicians, politicians, and third-party payers

Kidney International

Volumn 77, Issue 6, 2010, Pages 479-480

  Szczech, Lynda ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; EDITORIAL; HEALTH CARE QUALITY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MORTALITY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC FIGURE; STROKE;

EID: 77949503880     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.496     Document Type: Editorial

References (12)

1. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619.
2. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
3. Besarab A, Goodkin DA, Nissenson AR. The Normal Hematocrit Study: follow-up. N Engl J Med 2008; 358: 433-434.
4. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
5. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
6. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-312.
7. Szczech LA, Barnhart H, Inrig J et al. Epoetin-alfa dose and achieved hemoglobin are associated with outcomes among patients with anemia and chronic kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) Trial. Kidney Int 2008; 74: 791-798.
8. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
9. Pfeffer MA, Burdmann EA, Chen C-Y et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
10. Szczech LA, Barnhart HX, Sapp S et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010; 77: 175-177.
11. NKF-DOQI. National Kidney Foundation. http://www. kidney.org/ professionals/KDOQI (accessed 31 October 2009).
12. Medicare Programs; End-Stage Renal Disease Prospective Payment System; Town Hall Meeting on End-Stage Renal Disease Prospective Payment System; Proposed Rule and Notice. Centers for Medicare & Medicaid Services. Federal Register 74, no.187 (September 2009). http://edocket. access.gpo.gov/2009/pdf/ E9-22486.pdf (accessed 31 October 2009).